This site is intended for healthcare professionals

Amarin receives European Commission approval for Vazkepa to reduce cardiovascular events.

Read time: 1 mins
Published:3rd Apr 2021
Amarin Corporation plc announced that following a review and approval recommendation by the European Medicines Agency (EMA), the European Commission (EC) has approved the marketing authorization application for Vazkepa (icosapent ethyl) to reduce the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides ( greater than 150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor. Amarin’s icosapent ethyl was approved for cardiovascular risk reduction by the FDA in December 2019 and is marketed in the U.S. under the brand name, Vascepa.
Condition: Cardiovascular Events
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights